[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"condbio:gastroesophageal-junction-adenocarcinoma:erbb2-gene":3},{"condition":4,"biomarker":5,"total":6,"trials":7},"Gastroesophageal Junction Adenocarcinoma","ERBB2 Gene",10,[8,16,22,29,36,43,49,55,61,67],{"nct_id":9,"title":10,"phases":11,"status":13,"updated_at":14,"content_modified":15},"NCT06764875","A Phase Ⅲ Study of Rilvegostomig in Combination With Fluoropyrimidine and Trastuzumab Deruxtecan as the First-line Treatment for HER2-positive Gastric Cancer",[12],"Phase 3","RECRUITING","2026-08-26T02:18:59.761994Z","2026-05-05T02:43:29.164625Z",{"nct_id":17,"title":18,"phases":19,"status":13,"updated_at":20,"content_modified":21},"NCT06532006","A Phase Ⅲ Clinical Study of HLX22 in Combination With Trastuzumab and Chemotherapy for the Treatment of Gastroesophageal Junction and Gastric Cancer",[12],"2026-08-26T02:17:06.985283Z","2026-05-05T02:43:28.114299Z",{"nct_id":23,"title":24,"phases":25,"status":13,"updated_at":27,"content_modified":28},"NCT05482893","Spevatamig (PT886) as Monotherapy or in Combination With Chemo and\u002For ICI, for the Treatment of Patients With Advanced Gastric, Gastroesophageal Junction, Pancreatic Ductal or Biliary Tract Carcinomas (the TWINPEAK Study)",[26],"Phase 1\u002FPhase 2","2026-08-26T02:16:36.513735Z","2026-07-19T19:36:05.117317Z",{"nct_id":30,"title":31,"phases":32,"status":13,"updated_at":34,"content_modified":35},"NCT04379596","Ph1b\u002F2 Study of the Safety and Efficacy of T-DXd Combinations in Advanced HER2-expressing Gastric Cancer (DESTINY-Gastric03)",[33],"Phase 2","2026-08-26T02:16:13.426928Z","2026-05-05T02:43:28.509515Z",{"nct_id":37,"title":38,"phases":39,"status":13,"updated_at":41,"content_modified":42},"NCT06364410","Testing the Combination of the Anticancer Drugs Trastuzumab Deruxtecan (DS-8201a) and Azenosertib (ZN-c3) in Patients With Stomach or Other Solid Tumors",[40],"Phase 1","2026-08-26T02:17:58.890423Z","2026-05-05T02:43:28.188138Z",{"nct_id":44,"title":45,"phases":46,"status":13,"updated_at":47,"content_modified":48},"NCT05187182","CA-4948 in Combination With FOLFOX\u002FPD-1 Inhibitor +\u002F- Trastuzumab for Untreated Unresectable Gastric and Esophageal Cancer",[40],"2026-08-26T02:18:20.384845Z","2026-05-05T02:43:26.773275Z",{"nct_id":50,"title":51,"phases":52,"status":13,"updated_at":53,"content_modified":54},"NCT06293898","Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors",[40],"2026-08-26T02:16:23.080181Z","2026-07-24T01:27:14.888332Z",{"nct_id":56,"title":57,"phases":58,"status":13,"updated_at":59,"content_modified":60},"NCT05872295","IKS014 in Advanced Solid Tumors That Express HER2",[40],"2026-08-26T02:19:16.454910Z","2026-07-05T05:32:16.816198Z",{"nct_id":62,"title":63,"phases":64,"status":13,"updated_at":65,"content_modified":66},"NCT05150691","A Phase 1\u002F2a Study of DB-1303\u002FBNT323 in Advanced\u002FMetastatic Solid Tumors",[26],"2026-08-26T02:16:32.589113Z","2026-05-05T02:43:29.396080Z",{"nct_id":68,"title":69,"phases":70,"status":71,"updated_at":72,"content_modified":73},"NCT06157892","A Study of Disitamab Vedotin With Other Anticancer Drugs in Solid Tumors",[33],"ACTIVE_NOT_RECRUITING","2026-08-03T02:40:44.217164Z","2026-04-29T02:57:57.142228Z"]